
RLAY Stock Forecast & Price Target
RLAY Analyst Ratings
Bulls say
Relay Therapeutics Inc. demonstrates a strong position in the biotechnology sector, driven by the success of its RLY-2608 candidate, which has shown a notable Overall Response Rate (ORR) of 67% in patients with kinase mutations, alongside an improvement in median progression-free survival (mPFS) to 11.4 months. The favorable clinical results, particularly for RLY-2608 in combination with existing therapies such as Faslodex, underscore the company's innovative approach to precision oncology and the therapeutic potential of its pipeline. Furthermore, with anticipated cash reserves of $781 million to support ongoing trials, Relay Therapeutics is well-positioned to navigate future developments and address investor concerns about trial scale and dosing, contributing to an optimistic outlook for the stock.
Bears say
Relay Therapeutics Inc. is facing a challenging financial outlook, projecting a full-year net loss of $2.15 per share for 2025, which reflects ongoing concerns about its clinical development pathways and operational performance. The company is at risk from multiple factors, including potential negative clinical data, regulatory approval failures, and competitive landscape threats, all of which could hinder the advancement of its drug candidates like RLY-4008 and RLY-2608. Furthermore, projected losses for 2024 were recorded at $2.36 per share, aligning closely with initial estimates, indicating persistent financial strain without any immediate signs of turnaround.
This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
RLAY Analyst Forecast & Price Prediction
Start investing in RLAY
Order type
Buy in
Order amount
Est. shares
0 shares